Cipla expects sequential recovery in North America on new product launches despite tariff uncertainty

Cipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compression, despite posting record revenue of ₹7,119 crore. EBITDA declined 33%, with margins narrowing significantly. Growth was driven by strong performance in India, Africa, and emerging markets, with the domestic business hitting an all-time high. The company remains focused on new product launches, including respiratory and peptide segments, and expects a recovery in the US business led by Ventolin supplies.

Raccontata daeconomictimes.indiatimes.comthehindubusinessline.comthehindu.com